𝔖 Bobbio Scriptorium

✦ LIBER ✦

2–39 Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene

✍ Scribed by Jordan, V.C.

Book ID: 122346360
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 57 KB
Volume: 16
Category: Article
ISSN: 1043-321X
DOI: 10.1016/S1043-321X(05)80142-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Continuing Outcomes Relevant to Evista:

Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene

✍ Wickerham, D.L. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 55 KB

2. A randomized, double-blind, multicent

2. A randomized, double-blind, multicentre crossover trial to evaluate in vivo inhibition of aromatase by Arimidex (ZD1033) (1 mg and 10 mg PO OD) in postmenopausal women with breast cancer

✍ J. Geisler; P.E. Lonning; M. Dowsett; N. King; S. Lundgren; L. Ottestad; P.O. Ko 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 290 KB

Switching to exemestane after 2–3 years

Switching to exemestane after 2–3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen: Abstracted from: Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081–92.

✍ Christina Davies 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 248 KB